Relay Therapeutics
RLAY | NASDAQ
$17.27
-$0.82 (-4.53%)
At close: Nov 16, 2026, 4:00 PM ET
$17.50
+$0.23 (+1.33%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Relay Therapeutics Company Profile
Company profile explainedCompany Profile
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Sanjiv K. Patel MBBS | Chief Executive Officer, President & Director |
| Thomas Catinazzo | Chief Financial Officer |
| David Elliot Shaw | Founder |
| Donald A. Bergstrom | President of Research & Development |
| Dorothee Kern | Founder |
| Jim Watters | Chief Scientific Officer |
| Mahesh Padval | Chief Pharmaceutical Development Officer |
| Mark Murcko | Founder & Independent Director |
| Matthew Jacobson | Founder |
| Peter Rahmer | Chief Corporate Development Officer |
| Soo-Yeun Lim | Senior Vice President & General Counsel |
Relay Therapeutics
| Country | United States |
| IPO Date | Jul 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 202 |
| CEO | Sanjiv K. Patel |
Contact Details
60 Hampshire Street Cambridge,
Massachusetts 02139 United States
Stock Details
| Ticker Symbol | RLAY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812364 |
| CUSIP Number | 75943R102 |
| ISIN Number | US75943R1023 |
| SIC Code | 2836 |
Recent News
- 5 days ago / seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
- 14 days ago / globenewswire.comRelay Therapeutics to Participate in Three Upcoming Investor Conferences in November
- 19 days ago / globenewswire.comRelay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
- 2 months ago / seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
- 3 months ago / fool.comRelay Therapeutics CFO Sells 17,717 Shares for $350,000
- 3 months ago / globenewswire.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in September
- 3 months ago / zacks.comRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
- 3 months ago / globenewswire.comRelay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
- 4 months ago / globenewswire.comRelay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Add to Watchlist
Select watchlists to add or remove RLAY